PhD Scientific Days 2024

Mental Health Sciences III.

Opposite effects of CGRP-related genes on migraine and depression

Előadó neve

Baksa, Dániel, PhD

Neptun code

BE9YSR

Előadó munkahelye

Department of Pharmacodynamics, Faculty of Pharmacy, Semmelweis University, Budapest, Hungary

Előadó telefonszáma

06205272302

Előadó e-mail címe

baksadan@gmail.com

Az előadás címe

Opposite effects of CGRP-related genes on migraine and depression

Szerző(k) neve és munkahelye

Dániel Baksa¹, Dóra Török¹, Gabriella Juhász¹

1: Department of Pharmacodynamics, Faculty of Pharmacy, Semmelweis University, Budapest, Hungary

Bemutatás módja

Szóbeli

Szekció

Mental Health Sciences III.

Language of the presentation

Hungarian

Preferred session

Mental Health Sciences

Összefoglaló szövege

Introduction Anti-calcitonin gene-related peptide (CGRP) migraine medications may also reduce symptoms of depression, a comorbid disease of migraine with overlapping genetic background.
Aims Here, we aimed to test the effect of polygenic risk score (PRS) of a CGRP-related gene set on migraine and depression.
Methods A sample of the UK Biobank database (Application no. 71718) was used (N=134,197) in our cross-sectional study. Migraine and depression status were based on ICD-10 codes (G43 and F32/F33, respectively), and we also used a questionnaire-based current depression score. The CGRP gene set was defined according to the Pathway Commons database (Ngenes = 29). PRS was calculated with LDpred2. To test the predictive value of the PRS, we performed linear regressions with R (4.1.2) separately on migraine, depression, and current depression score.
Results The CGRP gene set PRS showed a significant risk effect on migraine (beta=0.4981, p=0.0067) but not on depression diagnosis, although a significant protective effect on current depression score (beta=-0.2466, p=0.0319) was detected.
Conclusion A CGRP-related gene set showed a risk effect on migraine, but a protective effect on current depression symptoms that might suggest a better mental health state among migraine patients with higher CGRP-related genetic risk.

Funding 2017-1.2.1-NKP-2017-00002; NAP2022-I-4/2022; TKP2021-EGA-25; 2019-2.1.7-ERA-NET-2020-00005, ERAPERMED2019-108; K 143391; ÚNKP-23-4-II-SE-2

University

Semmelweis University

Supervisor

None

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

Kind

Szabad

Status

elfogadva

Accepted presentation method

szóbeli

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

4105

Start

16:45

End

16:55